Antibodies, boosters, and optimizing SARS-CoV-2 vaccines for transplantation: A call for more research
- PMID: 34241964
- PMCID: PMC8441892
- DOI: 10.1111/ajt.16758
Antibodies, boosters, and optimizing SARS-CoV-2 vaccines for transplantation: A call for more research
Abstract
Despite emerging data suggesting reduced antibody responses among solid organ transplant recipients following SARS-CoV-2 vaccine, critical unanswered questions remain. The clinical implications of the reduced humoral response need to be assessed through prospective studies. Studies are likewise needed to inform which vaccine dosing strategies result in improved immunity and if such approaches maximize protection against severe infection in the vulnerable transplant population.
© 2021 The American Society of Transplantation and the American Society of Transplant Surgeons.
Comment in
-
Boosters and optimizing SARS-CoV-2 vaccine for transplantation: No time to wait.Am J Transplant. 2022 Jan;22(1):328-329. doi: 10.1111/ajt.16788. Epub 2021 Aug 23. Am J Transplant. 2022. PMID: 34370901 Free PMC article. No abstract available.
-
Protecting kidney transplant recipients against SARS-CoV-2 infection: A third dose of vaccine is necessary now.Am J Transplant. 2022 Apr;22(4):1275-1276. doi: 10.1111/ajt.16829. Epub 2021 Sep 7. Am J Transplant. 2022. PMID: 34467623 Free PMC article. No abstract available.
References
-
- US Food and Drug Administration. Antibody testing is not currently recommended to assess immunity after COVID-19 vaccination: FDA safety communication. Accessed July 21, 2021. https://www.fda.gov/medical-devices/safety-communications/antibody-testi....
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous